Novo Nordisk posts Q3 sales of obesity drug Wegovy

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today,
Novo Nordisk AS (NVO) Q3 2024 Earnings Call Highlights: Robust Sales Growth and Strategic ...
Novo Nordisk AS (NVO) reports strong financial performance with a 24% sales increase, driven by demand for diabetes and obesity treatments, despite challenges in supply and rising R&D costs.
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Novo Misses Overall Q3 Revenue Despite Beating Wegovy Sales Forecast, Narrows 2024 Outlook
Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year guidance for revenue and operating profit.
Novo Nordisk Q3 earnings: Wegovy sales soar 79% year-over-year
Novo Nordisk (NVO) revealed mixed third quarter results, the pharmaceutical giant narrowing its full-year sales growth guidance while posting a 79% year-over-year sales increase for its landmark weight-loss drug Wegovy.
Novo Nordisk: Q3 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
Novo beats Eli Lilly in Q3 sales for obesity drug
Novo Nordisk (NVO) reported better than expected sales for its weight loss therapy Wegovy with its Q3 2024 financials on Wednesday after Eli Lilly (LLY), its rival in the obesity drug market, posted a rare quarterly miss for its GLP-1 drug,
Novo Nordisk Q3 Wegovy sales beat forecast, shares rise
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Novo Nordisk shares jump 8% after Wegovy sales beat expectations
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Novo Nordisk Reports Strong Growth in 2024
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...